RxDoctor Payments Data

Gary Berman, MD

Cardiovascular Disease · West Orange, NJNPI 1609981281

Payments from drug & device makers

$6,814in general payments, 2019–2025

Across 21 payments — averaging $324.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$5K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Boehringer Ingelheim$280
  • Boston Scientific$159
  • Novo Nordisk$141
  • Johnson & Johnson$124
  • plus $171 from 7 others

What the payments were for

  • Consulting fees$1,30019%
  • Speaking & faculty fees$4,03859%
  • Travel & lodging$6029%
  • Food & beverage$78812%
  • Education$220%
  • Entertainment$641%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,814 in reported general payments places this provider in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$315,600
Medicare patients
655
Services billed
3,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$178,739
JardianceEmpagliflozin132$172,542
XareltoRivaroxaban59$75,171
Repatha SureclickEvolocumab56$64,528
FarxigaDapagliflozin Propanediol21$33,281
EntrestoSacubitril/Valsartan17$32,706
Carvedilol ErCarvedilol Phosphate48$28,849
MounjaroTirzepatide21$20,958
VascepaIcosapent Ethyl38$19,369
Icosapent Ethyl32$17,300
Rosuvastatin Calcium928$16,816
EdarbyclorAzilsartan Med/Chlorthalidone31$13,932
Olmesartan Medoxomil413$13,446
Ezetimibe368$8,926
Nebivolol Hcl110$7,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$178,739151 claims
Boehringer IngelheimJardiance$280$172,542132 claims
Johnson & JohnsonXarelto$124$75,17159 claims
AstraZenecaFarxiga, Brilinta$16$39,31933 claims
NovartisEntresto$17$32,70617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →